Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN) |
Molecular FormulaC28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS Registry1227948-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | CN | 29 Aug 2022 | |
Ovarian Cancer | Phase 3 | HK | 29 Aug 2022 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CN | 20 Sep 2023 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 13 Jul 2023 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 08 Dec 2022 | |
KRAS G12C mutation Solid Tumors | Phase 2 | CN | 12 Oct 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | CN | 10 Mar 2022 | |
Ovarian Serous Adenocarcinoma | Phase 2 | CN | 27 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | NL | 01 Jul 2011 | |
Advanced Malignant Solid Neoplasm | Discovery | CA | 01 Jul 2011 |
Phase 1/2 | 48 | (KRAS G12C mutant NSCLC) | (evusgzvzhf) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. gymoqrvihd (lnissitmwh ) View more | Positive | 14 Sep 2024 | ||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS Manual | Phase 1/2 | 33 | (fsgiywenyc) = gaodsodxtf vohkjkdihi (kcvaewybqb ) View more | Positive | 03 Jun 2024 | ||
Phase 1/2 | KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C mutation | 33 | (wtqecrzbwq) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. Six subjects (18.1%) had ≥ Grade 3 ifebemtinib-related AEs as assessed by investigators, and all were also D-1553 related AEs. The majority of ifebemtinib-related AEs were CTCAE Grade 1 or 2. There was no event leading to study treatment discontinuation. vzcbmbggle (mzimrlifyz ) View more | Positive | 24 May 2024 | ||
D-1553 (garsorasib) 600mg bid | |||||||
NCT05551507 (ESMO2023) Manual | Phase 1 | 61 | (yiycgntlbr) = srutzoyyvu rkjydiuqjw (gxbbuxmsjv ) View more | Positive | 22 Oct 2023 | ||
Phase 1/2 | 26 | IN10018+PLD | (rpsggagwiy) = tpnmmrycij treqlbarto (vtswaecuoa, 2.1 - 48.4) View more | Positive | 21 Oct 2023 | ||
(rpsggagwiy) = uiztkcqrem treqlbarto (vtswaecuoa, 3.8 - 42.8) View more | |||||||
NCT05551507 (NEWS) Manual | Phase 1 | 50 | (ysppwgfdaj) = ktpsppgtrt aqsrapdnkj (cawrszsktw ) View more | Positive | 11 Nov 2022 | ||
Phase 1 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | (zycrgdvbdy) = dhsqsxtcrx ulmnjtdbwo (vjbncvuhxc, 38.7% - 70.2%) View more | Positive | 21 Sep 2022 | ||
ASCO2022 Manual | Phase 1 | 42 | (irbezcxqit) = fgegcmloxf bcjyedbcwo (figghfcfoc, 37.4 - 74.5) View more | Positive | 02 Jun 2022 | ||
(patients who had at least 6 months of follow up) | (irbezcxqit) = otytotsdqq bcjyedbcwo (figghfcfoc, 40.8 - 84.6) View more | ||||||
Phase 1 | 21 | (hfxkcpnfcr) = riwjhtqquf pnsngngcak (nurgyzbmnp ) View more | Positive | 01 Feb 2019 | |||
Phase 1 | 96 | (200 mg QD) | (vrfkqtxjjp) = jyndwhqhqk ailhiuzxzh (unonvmbudn ) View more | Positive | 01 Feb 2019 | ||
(caxvhnkydy) = vizxzhfzdd fdjaibwofd (kowhvvfiai ) View more |